Abstract
Macrophage migration inhibiting factor (MIF) is expressed by both immune and tumor cells and MIF overexpression is increasingly recognized as implicated in worse outcomes in melanoma patients and thus is a novel therapeutic target for melanoma. This is particularly important as although checkpoint inhibitor blockade has positively impacted advanced melanoma outcomes, there are few treatment options for non-responders (primary resistance) or those who have resistance after initial response (secondary resistance).
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call